(336) Targeting Serpinb9 via Gemcitabine-based SiRNA/Drug Nanocarrier to Improve Pancreatic Cancer Therapy

Introduction: Granzyme B is a potent cytotoxic molecule produced by cytotoxic T cells and NK cells to kill cancer cells. Serpinb9 is an endogenous inhibitor of granzyme B and is co-expressed in cytotoxic T cells to protect themselves from self-inflicted damage. Interestingly, many types of cancer cells also co-express serpinb9 and granzyme B. Targeting serpinb9 has been reported to improve cancer immune therapy. However, the impact of serpinb9 on the effects of chemotherapy drugs remains to be investigated.